Calithera Bio Receives a Buy from JMP SecuritiesBy Ryan Adsit
According to TipRanks.com, King is a 2-star analyst with an average return of 0.5% and a 45.1% success rate. King covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Syndax Pharmaceuticals Inc, and Karyopharm Therapeutics.
Calithera Bio has an analyst consensus of Hold, with a price target consensus of $1.
The company has a one year high of $8.85 and a one year low of $2.20. Currently, Calithera Bio has an average volume of 172.7K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CALA in relation to earlier this year. Most recently, in July 2016, Susan Molineaux, the President & CEO of CALA bought 29,385 shares for a total of $53,218.
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company, which focuses on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.